

RNS Number : 7577X
Trellus Health PLC
28 April 2023

Trellus Health plc
("Trellus Health" or the "Company")

Notice of Results
Investor Presentation

LONDON, U.K. AND NEW YORK, U.S. (28 April 2023). Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, personalized resilience-driven self-management solution for chronic health conditions at their intersection with mental health, announces that it expects to report its final results for the year ended 31 December 2022 on 23 May 2023.

Investor Presentation

Dr. Marla Dubinsky, CEO and Co-Founder, and Steve Young, Chief Financial Officer, will provide a live presentation relating to the Full Year Results via Investor Meet Company on 23rd May 2023 at 5:00pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Trellus Health plc via:

<https://www.investormeetcompany.com/trellus-health-plc/register-investor>

Investors who already follow Trellus Health plc on the Investor Meet Company platform will automatically be invited.

For further information please contact:

Trellus Health plc
Dr. Marla Dubinsky, CEO and Co-Founder
Dr. Daniel Mahony Chairman

<https://trellushealth.com/>
Via Walbrook PR

Singer Capital Markets (Nominated Adviser and Broker) **Tel: +44 (0)20 7496 3000**
Aubrey Powell / Jen Boorer

Walbrook PR
Paul McManus / Sam Allen / Phillip Marriage

Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
Mob: +44 (0)7980 541 893 / 07748 651 727 / 07867 984 082

About Trellus Health plc (www.trellushealth.com)

Trellus Health (LSE: TRLS) is the first resilience based digital health company focused on the intersection of chronic illness and mental health. Trellus Health integrates its proprietary resilience-based methodology with the technology, tools and team to deliver a whole-person technology-enhanced experience that results in relieving disease burden, building self-management skills and promoting individual health behaviours that enable thriving in the face of a chronic condition. Through its TrellusElevate™ connected health platform and companion App, the company addresses both physical and behavioural health together, in context, to improve outcomes and reduce healthcare costs across the healthcare ecosystem.

The Company was initially focused on inflammatory bowel disease ("IBD"), which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis but has now added Irritable Bowel Syndrome ("IBS"). Given the common struggles of self-management, Trellus Health considers its approach to have potential utility and demand across many chronic conditions.

The TrellusElevate™ platform is the Company's proprietary connected health platform that incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers. Patients with IBD treated using the methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following starting the program².

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both with decades of combined experience in IBD and psychogastroenterology, respectively. Trellus Health's patent-pending GRITT™ resilience assessment and personalized resilience training methodology was developed and validated at the Mount Sinai Health System to build resilience and wellness for improved outcomes at lower cost.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information on Trellus Health, visit: www.trellushealth.com

1) Source: <https://www.cdc.gov/chronicdisease/about/costs/index.htm>)

2) Source: <https://www.sciencedirect.com/science/article/pii/S1542356521012258>)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage

with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOREDFLXZLBBBX Anonymous (not verified) Notice of Results

<http://www.DigitalLook.com>

33467230 A Fri, 04/28/2023 - 07:00 LSE RNS Advance Notice of Results TRLS